The dose-escalation phase studied the effectiveness and safety of TKM-PLK1 in patients with lymphoma or advanced solid tumors at doses ranging from 0.15 to 0.9 mg/kg weekly followed by one drug-free week. The gene discussed is PLK1; the disease is lymphoma.